NCLT issues notice on SEBI intervention in minority shareholders' petition

Sebi InvestigationRegulatory & Legal View source PDF Explain this filing

JINDALPOLY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.4%Reaction day

₹770.00

prior close

₹732.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.0%-4.4% vs market

Packaging peers, median of 62sector-0.6%-3.8% vs sector

On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 3.8 pts less than its Packaging peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+2.5

15m

+2.1

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.4-0.0-4.4-0.6-3.8

Next day

-5.5+2.5-8.0+1.2-6.6

-8.3+3.7-12.0+1.4-9.7

-7.2+4.9-12.1+2.5-9.7

-7.7+4.3-12.0+2.1-9.8

-5.3+5.5-10.8+1.6-6.9

-5.5+6.6-12.0+2.1-7.6

15d

-4.6+10.3-14.9+3.6-8.2

-9.0+7.7-16.6+1.4-10.4

-4.5+13.7-18.2+0.8-5.3

-10.9+19.1-30.0+3.9-14.8

UpDownMarket · Nifty Microcap 250Sector · Packaging peers, median of 62Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NCLT New Delhi issued notice on April 9, 2026, on SEBI's intervention application in a petition filed by minority shareholders (Mr. Ankit Jain & Ors.). SEBI has submitted a preliminary report in the matter. The company has not yet received a copy of the NCLT order. The matter is sub-judice; no penalties, restrictions or sanctions have been imposed. The company says all transactions were carried out in compliance with applicable laws and SEBI requirements.

Likely market impact

Ongoing legal/regulatory scrutiny creates a near-term overhang. No financial hit yet, but adverse findings could pressure the stock and minority shareholders.